Abstract
The replacement of benzene rings with sp 3-hybridized bioisosteres in drug candidates generally improves pharmacokinetic properties while retaining biological activity 1–5. Rigid, strained frameworks such as bicyclo[1.1.1]pentane and cubane are particularly well suited as the ring strain imparts high bond strength and thus metabolic stability on their C–H bonds. Cubane is the ideal bioisostere as it provides the closest geometric match to benzene 6,7. At present, however, all cubanes in drug design, like almost all benzene bioisosteres, act solely as substitutes for mono- or para-substituted benzene rings 1–7. This is owing to the difficulty of accessing 1,3- and 1,2-disubstituted cubane precursors. The adoption of cubane in drug design has been further hindered by the poor compatibility of cross-coupling reactions with the cubane scaffold, owing to a competing metal-catalysed valence isomerization 8–11. Here we report expedient routes to 1,3- and 1,2-disubstituted cubane building blocks using a convenient cyclobutadiene precursor and a photolytic C–H carboxylation reaction, respectively. Moreover, we leverage the slow oxidative addition and rapid reductive elimination of copper to develop C–N, C–C(sp 3), C–C(sp 2) and C–CF 3 cross-coupling protocols 12,13. Our research enables facile elaboration of all cubane isomers into drug candidates, thus enabling ideal bioisosteric replacement of ortho-, meta- and para-substituted benzenes.
Original language | English |
---|---|
Pages (from-to) | 513-518 |
Number of pages | 7 |
Journal | Nature |
Volume | 618 |
Issue number | 7965 |
Early online date | 4 Apr 2023 |
DOIs | |
Publication status | Published - 15 Jun 2023 |
Bibliographical note
Funding Information:We thank Z. Dong, P. Sarver, Y. Liang, C. Oswood, W. Liu and M. Heilmann for discussions; I. Pelcer and K. Conover for assistance with NMR spectroscopy; R. Lambert for assistance with the preparation of this paper; J. Piesvaux, J. P. Imredy, R. L. Kraus and B. Lacey for help with biological profiling; and A. Beard, M. Darlak, S. McMinn, L. Nogle, M. Pietrafitta, D. Smith and Y. Ye (all Merck & Co., Inc.) for help with reverse-phase chromatography. The research was supported by the NIH National Institute of General Medical Sciences (NIGMS), the NIH (R35GM134897-03), the Princeton Catalysis Initiative, and kind gifts from Merck & Co., Inc., Bristol-Myers Squibb (BMS), Celgene, Genentech, Janssen Research and Development LLC, and Pfizer. M.P.W. was supported by the Deutsche Akademie der Naturforscher Leopoldina (LPDS 2018-16). F.B. was funded by the German Research Foundation (DFG) – 421436809, and J.D. was supported by an SNSF Early Postdoc.Mobility fellowship.
Data availability:
All data are available in the main text or in the Supplementary information.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.